New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
05:22 EDTPBMDPrima BioMed appoints Marc Voigt as CEO
The board of Prima BioMed announces that Marc Voigt has been appointed as CEO of Prima. Voigt, Prima's Chief Business Officer and CFO as well as General Manager of the company's European Operations, replaces U.S. based Matthew Lehman who will step down from the board but remain as an adviser to the company to facilitate an orderly transition. The decision follows the company's recent shift in its operational focus to Europe, where its clinical trials and manufacturing of CVac have been centralised to generate cost savings and enhance operational efficiencies. The company's European manufacturing facility is based in Leipzig, Germany where Prima benefits from a significant funding grant from the Saxony Development Bank to carry out its CVac development program in Europe.
News For PBMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
10:53 EDTPBMDPrima BioMed to host conference call
Subscribe for More Information
October 14, 2014
08:59 EDTPBMDPrima BioMed announces Immutep IMP321 receives Australian notice of allowance
Prima BioMed announced that Immutep S.A. has received a Notice of Allowance from the Australian Patent Office for Patent Application AU 2008306576 "Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response". As announced on 2 October Prima has reached an agreement to acquire Immutep subject to obtaining shareholder approval at its AGM to increase its share placement capacity to fund the acquisition. The AGM will be held on November 14. The patent provides protection for the use of soluble recombinant LAG-3 Ig, or IMP321, or derivatives thereof, notably in combinations, in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in the blood. This invention is currently in clinical trials for the treatment of cancer and the broad claims allowed will provide options for numerous clinical applications. By increasing the number of monocytes or antigen presenting cells in the blood, IMP321 can stimulate increased cytotoxic T cell responses against cancer antigens. Immutep has conducted clinical trials using IMP321 as a monotherapy, an adjuvant and in combination with chemotherapy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use